 MONT-SAINT-GUIBERT, Belgium, June 11, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced preliminary data from the Phase 1 IMMUNICY-1 trial of CYAD-211 for the treatment of relapsedrefractory multiple myeloma rr MM patients were presented at the European Hematology Association EHA 2021 Virtual Congress. 